Apollo in Advanced Talks to Buy J&J Orthopaedics Unit for $20 Billion

Key Facts

1Apollo Global Management is in advanced talks to acquire Johnson & Johnson's orthopaedics unit.

2The potential deal is valued at approximately $20 billion.

In a move reflecting the trend of global corporations streamlining operations to focus on high-growth segments, Johnson & Johnson is nearing a major divestiture. According to reports, Apollo Global Management is in advanced talks to acquire Johnson & Johnson's orthopaedics unit. The potential deal is valued at approximately $20 billion, marking a significant strategic shift for both entities involved.

These negotiations align with Johnson & Johnson's ongoing strategy to refine its corporate focus by prioritizing its pharmaceutical and medtech divisions. For Apollo, the acquisition represents a major deployment of capital into large-scale private equity opportunities within the healthcare sector. Per market data, analysts view this $20 billion divestiture as a potential catalyst for unlocking shareholder value and sharpening J&J's operational efficiency.

JNJ shares stood at $265.58 (at close September 11, 2026), having reached a day high of $270.4 during the session. With no major healthcare-specific catalysts in the immediate upcoming calendar, investors will focus on official confirmations regarding the deal's progress. Based on recent trading data, the $270.4 level serves as a notable resistance point for the stock in the near term.